Table 4.
Descriptions of Studied Pharmaceutical Interventions
| Pharmaceutical Agent | Description | Used in Article |
|---|---|---|
| Ibodutant | A selective neurokinin-2 (NK2) receptor antagonist. | Tack et al18 |
| Neomycin | An aminoglycoside antibiotic. | Pimentel et al19 |
| Crofelemer | Inhibits cAMP-mediated chloride ion secretion in Caco-2 and T84 cells, and therefore has antisecretory activity. | Mangel et al20 |
| Eluxadoline | A mixed μ- and κ-opioid receptor agonist and δ-opioid receptor antagonist, that acts locally in the enteric nervous system, possibly decreasing adverse effects on the central nervous system. | Lacy et al21 |
| Renzapide | A benzamide derivative with not only 5-HT4 receptor full agonist properties, but also 5-HT3 receptor antagonist properties. | George et al14 |
| Ramosetron hydrochloride | A potent and selective synthetic 5-HT 3 receptor antagonist. | Matsueda et al15 |
| Alosetron | A potent, highly selective 5-HT3 receptor antagonist. | Bardhan et al.17 Camilleri et al.16 |